In a nutshell This study assessed whether patients with metastatic non-small-cell lung cancer (mNSCLC) would benefit from treatment using durvalumab (Imfinzi) with or without tremelimumab (CP-675,206) as a later treatment. The authors concluded that durvalumab showed improvement in overall survival (OS) and...
Read More
In a nutshell This study examined how effective S-1 (Teysuno) chemotherapy is for patients with advanced non-small cell lung cancer (NSCLC) following initial chemotherapy treatment. The results showed that S-1 improved patients’ survival without NSCLC worsening but increased the number of side effects. Some background Treatment for patients...
Read More
In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients. Some background NSCLC accounts for...
Read More
In a nutshell This study examined if certain immunotherapy drugs increased the risk of developing side effects in the gut in patients with cancer also receiving chemotherapy. The results showed that immunotherapy drugs increased the risks of developing gut-related side effects compared to chemotherapy alone. Some background Immunotherapy drugs that...
Read More
In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...
Read More
In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...
Read More
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read More
In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...
Read More
In a nutshell This study evaluated the effectiveness and safety of three different ALK tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The authors concluded that these inhibitors were similarly effective, but elderly patients over age 65 were more likely to develop side effects. Some background NSCLC is...
Read More
In a nutshell This trial is examining the effectiveness of pegilodecakin (AM0010) when it is used with pembrolizumab (Keytruda) to treat patients with advanced non-small cell lung cancer (NSCLC). The main outcome to be measured will be tumor responses to the treatment. This trial is recruiting in multiple locations around the United States. The...
Read MoreIn a nutshell This study investigated the long-term survival of patients with non-small cell lung cancer (NSCLC) treated with nivolumab (Opdivo). They found that this treatment is well tolerated and improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC). Over...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...
Read More
